Table 1 Comparison of clinical efficacy between the two groups
Group | Recurrence group (n = 41) | Non-recurrence group (n = 155) | \(x\)2/t value | P value |
|---|---|---|---|---|
Case number (male/female) | 27/14 | 109/46 | 0.093 | 0.761 |
Age (year) | 55.28 ± 4.01 | 55.87 ± 3.98 | − 0.784 | 0.434 |
BMI (kg/m2) | 25.67 ± 3.87 | 25.32 ± 3.28 | 0.534 | 0.594 |
Creatine (mmol/L) | 72.89 ± 19.89 | 74.52 ± 13.29 | − 0.496 | 0.622 |
Cardiac troponin I | 7.59 ± 3.27 | 7.87 ± 3.71 | − 0.44 | 0.66 |
C-reactive protein | 2.41 ± 0.98 | 2.14 ± 0.26 | − 1.745 | 0.083 |
Blood urea nitrogen | 4.76 ± 0.82 | 4.45 ± 1.46 | 1.785 | 0.077 |
Uric acid (umol/L) | 205.98 ± 49.87 | 221.95 ± 39.87 | − 1.896 | 0.063 |
Amino terminal B type Pro-BNP (ng/L) | 320.87 ± 92.38 | 289.67 ± 89.72 | − 1.934 | 0.055 |
History of diabetes (n,%) | 1 (2.44) | 16 (10.32) | 2.328 | 0.169 |
History of hypertension (n,%) | 11 (26.83) | 59 (38.06) | 1.917 | 0.166 |
History of coronary heart disease (n,%) | 13 (31.71) | 37 (25.16) | 0.697 | 0.404 |
History of heart failure (n,%) | 6 (14.63) | 9 (5.81) | 2.946 | 0.086 |
Stroke /TIA (n, %) | 2 (4.88) | 11 (7.10) | 0.169 | 0.681 |
ARB/ACEI (n, %) | 23 (56.10) | 69 (50.12) | 1.746 | 0.186 |
β blocker (n, %) | 12 (29.27) | 29 (18.71) | 2.185 | 0.139 |
Amiodarone (n, %) | 9 (21.95) | 16 (10.32) | 3.94 | 0.064 |
Propafenone (n, %) | 1 (0.02) | 5 (3.23) | 0.068 | 0.795 |
Characteristics of radiofrequency ablation (n, %) | ||||
Additional linear ablation (mm) | 12 (29.27)29 | 34 (21.94) | 0.97 | 0.325 |
Additional CFAE ablation | 6 (14.63)35 | 13 (8.39) | 0.931 | 0.335 |